The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.
about
Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathwaysAdenosine receptors: therapeutic aspects for inflammatory and immune diseases.Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.Methotrexate induced pancytopenia.Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptorFunctionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).Immune cell regulation by autocrine purinergic signalling.A₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.Purinergic regulation of neutrophil chemotaxis.PharmGKB summary: methotrexate pathway.A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats.CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.G protein-coupled receptors as therapeutic targets for multiple sclerosis.The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis ratsG protein-coupled receptor connectivity to NF-kappaB in inflammation and cancer.Purinergic signalling in the musculoskeletal system.Adenosine receptors and cancer.MicroRNA-206 is involved in the pathogenesis of ulcerative colitis via regulation of adenosine A3 receptor.Emerging drugs for the treatment of dry eye disease.Neurotransmitter signaling in the pathophysiology of microglia.Changing trends in the treatment of dry-eye disease.Adenosine A3 Receptor: A promising therapeutic target in cardiovascular disease.Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.G protein coupled receptors signaling pathways implicate in inflammatory and immune response of rheumatoid arthritis.Targeting methionine cycle as a potential therapeutic strategy for immune disorders.Control of enteric neuromuscular functions by purinergic A(3) receptors in normal rat distal colon and experimental bowel inflammationPurinergic Signalling: Therapeutic Developments.Adenosine A3 receptor agonists: do recent findings offer new hope in chronic pain treatment?The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases.Emerging drugs for psoriasis
P2860
Q24646643-1C7C8B2C-9D89-41F7-A752-2C1DC2E202C6Q24651475-67545688-BEF9-4262-8422-334BC9EADBFAQ33543585-0145281E-567C-4B82-8453-47B1B26B61BDQ33804885-25409ABA-6086-4604-8305-43B33AC06FE6Q33894529-BEC178F1-3223-4FE9-A16E-A06A9A731672Q33926350-8DCC81FC-924E-4670-AD12-844385AC319DQ34025783-5FD0B8A4-38BF-465E-8E9D-3F6EFCF89628Q34412639-918F60A5-0A75-4567-9846-DAF3A2E11804Q34425713-09E93DE9-87B1-4526-B5FC-A7B88F0CB4D4Q35115680-FC6148C2-5E5A-43F7-A2DD-784B1B236A26Q35235736-323A0BC6-64A1-4482-AAD8-225D25C22850Q36327138-15B16D32-FCED-42B8-8E58-A722FED1E787Q36725267-41345DF7-E2F5-4646-BDC1-6C26F06933C6Q37112554-993F187E-FF6B-40ED-9AA9-FCCB371139A4Q37180330-6C6CF1AF-B6B7-429A-BD27-1624F832374DQ37293340-1D4D5342-3723-46ED-9E0A-38DC8536724EQ37468714-9A63FB03-65AF-4BA8-BBB4-F19935DA2988Q37565200-69ACC567-0D19-46A2-95C3-7F82DF0AF452Q37702348-DF348483-F857-4B09-A122-83F73E1BF2BFQ38102006-817C1ED5-5237-407D-AE46-6231C25119AAQ38102686-3879ABB1-A2A1-4203-9306-1F2B3E6AAAD4Q38148616-679C5B73-B517-4471-8B38-6472ABBF694EQ38691918-56533CCC-2817-465C-94BA-5646D8B0DA30Q38991972-15A7BE6D-8559-411B-84BE-B5F2C42F506BQ39017722-A7BFC248-3371-45F6-BBDA-5C2E8940C6CFQ40075590-E8B7D353-01FD-447C-8C43-AF79985D3863Q41474088-E5BFC10D-A095-4043-BA82-C3D3DBF1BFC9Q42367885-21005F9B-6A17-47A9-AEA8-4DCAA3350D2AQ47570950-F905DDA9-A8A0-4BC8-B437-FBD5BD3A2764Q55261560-4BF3E6EF-F759-403F-8C1F-C0AE855B2F73Q57244448-D6B95FFE-5700-4710-8260-3273DF3B8F8B
P2860
The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The anti-inflammatory effect o ...... rapy for rheumatoid arthritis.
@ast
The anti-inflammatory effect o ...... rapy for rheumatoid arthritis.
@en
type
label
The anti-inflammatory effect o ...... rapy for rheumatoid arthritis.
@ast
The anti-inflammatory effect o ...... rapy for rheumatoid arthritis.
@en
prefLabel
The anti-inflammatory effect o ...... rapy for rheumatoid arthritis.
@ast
The anti-inflammatory effect o ...... rapy for rheumatoid arthritis.
@en
P2093
P2860
P1476
The anti-inflammatory effect o ...... rapy for rheumatoid arthritis.
@en
P2093
Avivit Ochaion
Michael H Silverman
Sara Bar-Yehuda
Shira Cohen
William D Kerns
P2860
P304
P356
10.1517/13543784.16.10.1601
P407
P577
2007-10-01T00:00:00Z